Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
Launched by UNIVERSITY HOSPITAL, ANTWERP · Oct 10, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Purpose: the aim of this study is to evaluate the potential beneficial antitumoral effect of LMWH enoxaparin in patients with locally advanced or metastatic NSCLC determined by the time to progression, the overall survival and the symptom control. LMWH will be added to a first line cisplatin-based chemotherapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Locally advanced or metastatic NSCLC (stage IIIB or IV)
- • Patients who are not candidates for radical combined modality treatments or high-dose radiation therapy
- • At least one measurable lesion according to RECIST criteria
- • Good performance status
- • Adequate haematological, renal and liver function
- • Written informed consent
- Exclusion Criteria:
- • Previous chemotherapy for NSCLC
- • Brain metastasis
- • History of cerebral haemorrhage, neurosurgery within 3 previous months or surgery within the past 6 months
- • Indication for anticoagulant therapy, thrombolytic therapy or antiplatelet therapy for cardiovascular disease
- • Concomitant therapy with an anti-angiogenesis agent
- • Contra-indication for LMWH
- • Life expectancy of \< 3 months
- • Serious concomitant systemic disease, uncontrolled arterial hypertension, active peptic ulcer or other condition which does not permit study treatment or follow-up required to comply with the study protocol
About University Hospital, Antwerp
University Hospital Antwerp is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital fosters a collaborative environment that integrates cutting-edge scientific inquiry with state-of-the-art medical practices. As a prominent sponsor of clinical trials, University Hospital Antwerp is committed to enhancing medical knowledge and improving treatment outcomes across a wide range of specialties, leveraging its expertise to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, Antwerp, Belgium
Liège, , Belgium
Patients applied
Trial Officials
Paul R Germonpre, MD PhD
Principal Investigator
Universiteit Antwerpen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials